1. COMBINATION OF TGR‐1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA. (June 2017) Authors: Lunning, M.A.; Vose, J.M.; Bierman, P.J.; Bociek, G.; Schreeder, M.T.; Siddiqi, T.; Blumel, S.M.; Cutter, K.; Pauli, E.K.; Bui, D.; Sportelli, P.; Miskin, H.P.; Purdom, M.; Weiss, M.S.; Fowler, N.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION. (12th June 2019) Authors: Mato, A.R.; Svoboda, J.; Luning Prak, E.T.; Schuster, S.J.; Tsao, P.Y.; Dorsey, C.; Sarmasti, L.M.; Becker, P.S.; Brander, D.M.; Nasta, S.; Landsburg, D.J.; King, C.M.; Morrigan, B.; Elwell, J.; Kennard, K.; Roeker, L.; Zelenetz, A.D.; Purdom, M.; Paskalis, D.; Sportelli, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗